Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells

被引:69
作者
Kortylewski, M
Heinrich, PC
Kauffmann, ME
Böhm, M
Mackiewicz, A
Behrmann, I
机构
[1] Rhein Westfal TH Aachen, Dept Biochem, D-52074 Aachen, Germany
[2] Poznan Tech Univ, Dept Canc Immunol, Sch Med Sci, Greatpoland Canc Ctr, PL-61866 Poznan, Poland
[3] Univ Munster, Dept Dermatol, D-48149 Munster, Germany
关键词
PD098059; proliferation; protein stability;
D O I
10.1042/0264-6021:3570297
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mitogen-activated protein kinases (MAPKs) extracellular signal-regulated protein kinase (ERK)1 and ERK2, involved in regulating cell growth and differentiation, are constitutively active in A375 and WM239 human melanoma cells. Using PD098059. an inhibitor of MAPK kinase (MEK), we investigated the role of persistently activated ERK1/2 in cell growth. The inhibition of MAPK activity induced a dose-dependent growth arrest in G(0)/G(1) phase. Correspondingly, we observed the upregulation of the cyclin-dependent kinase (Cdk) inhibitor p27/Kip1 and hypophosphorylation of the retinoblastoma protein. Further studies showed that PD098059 treatment significantly decreased Cdk2 kinase activity, most probably owing to an augmented level of p27/Kip1 associated with cyclin E-Cdk2 complexes. The accumulation of p27/Kip1 protein in A375 cells was attributed to its increased stability. Our findings suggest that constitutively active ERK1/2 kinases contribute to the growth of melanoma cells by negative regulation of the p27/Kip 1 inhibitor.
引用
收藏
页码:297 / 303
页数:7
相关论文
共 27 条
[1]  
ALBINO AP, 1992, ONCOGENE, V7, P2315
[2]   Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells [J].
Baldassarre, G ;
Belletti, B ;
Bruni, P ;
Boccia, A ;
Trapasso, F ;
Pentimalli, F ;
Barone, MV ;
Chiappetta, G ;
Vento, MT ;
Spiezia, S ;
Fusco, A ;
Viglietto, G .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (07) :865-874
[3]   RAS MUTATIONS IN HUMAN-MELANOMA - A MARKER OF MALIGNANT PROGRESSION [J].
BALL, NJ ;
YOHN, JJ ;
MORELLI, JG ;
NORRIS, DA ;
GOLITZ, LE ;
HOEFFLER, JP .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (03) :285-290
[4]   Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice [J].
Borner, C ;
Wadl, HS ;
Fellay, I ;
Selzer, E ;
Polterauer, P ;
Jansen, B .
MELANOMA RESEARCH, 1999, 9 (04) :347-350
[5]   Essential role for oncogenic Ras in tumour maintenance [J].
Chin, L ;
Tam, A ;
Pomerantz, J ;
Wong, M ;
Holash, J ;
Bardeesy, N ;
Shen, Q ;
O'Hagan, R ;
Pantginis, J ;
Zhou, H ;
Horner, JW ;
Cordon-Cardo, C ;
Yancopoulos, GD ;
DePinho, RA .
NATURE, 1999, 400 (6743) :468-472
[6]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[7]   Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation [J].
Englaro, W ;
Bertolotto, C ;
Buscà, R ;
Brunet, A ;
Pagès, G ;
Ortonne, JP ;
Ballotti, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) :9966-9970
[8]   Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma [J].
Florenes, VA ;
Lu, C ;
Bhattacharya, N ;
Rak, J ;
Sheehan, C ;
Slingerland, JM ;
Kerbel, RS .
ONCOGENE, 1999, 18 (04) :1023-1032
[9]   Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma -: Inverse correlation with disease-free survival [J].
Florenes, VA ;
Mælandsmo, GM ;
Kerbel, RS ;
Slingerland, JM ;
Nesland, JM ;
Holm, R .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (01) :305-312
[10]  
Gemma A, 1996, INT J CANCER, V68, P605, DOI 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO